Startup profile · funding coverage
Nouscom funding, valuation and investors
Clinical-stage developer of neoantigen-targeted immunotherapies for cancer interception and treatment.
Keep track of Nouscom
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series D
$135M (EUR120M; company-disclosed equivalent) · October 19, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$135M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Basel, Switzerland
Investors in latest funding
Lead: M Ventures , Revelation Partners
Other: Angelini Industries (through Angelini Investments) , European Investment Bank (through Aurea) , Neva SGR , 5AM Ventures , Andera Partners , Angelini Ventures , Bpifrance (InnoBio2) , CDP Venture Capital (Large Ventures Fund) , EQT Life Sciences , Indaco Venture Partners , Panakes Partners , Versant Ventures , XGEN Ventures
Overview
Nouscom is a Basel-based clinical-stage biotechnology company developing immunotherapies, including investigational NOUS-209. On October 19, 2026 it announced a closed Series D of $135M, the company-disclosed equivalent of EUR120M, co-led by M Ventures and Revelation Partners. The financing supports a global registration-enabling trial; clinical efficacy and eventual approval are not established by the financing.
Why Nouscom is interesting
Its Series D funds a registration-enabling development step, making trial execution and evidence quality central to the investment case.
Product & use cases
Investigational off-the-shelf and personalized neoantigen immunotherapy programs. NOUS-209 is being developed for cancer interception and treatment settings; it is not presented here as an approved prevention product.
Funding history (newest first)
Series D
2026-10-19 $135M (EUR120M; company-disclosed equivalent)- M Ventures (lead)
- Revelation Partners (lead)
- Angelini Industries (through Angelini Investments) (participant)
- European Investment Bank (through Aurea) (participant)
- Neva SGR (participant)
- 5AM Ventures (participant)
- Andera Partners (participant)
- Angelini Ventures (participant)
- Bpifrance (InnoBio2) (participant)
- CDP Venture Capital (Large Ventures Fund) (participant)
- EQT Life Sciences (participant)
- Indaco Venture Partners (participant)
- Panakes Partners (participant)
- Versant Ventures (participant)
- XGEN Ventures (participant)
Investors in our directory
Funds linked from Nouscom's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
The clinical-stage investment case depends on interpretable outcomes, recruitment, follow-up, manufacturing consistency and financing through evidence milestones. An off-the-shelf design does not itself establish superiority to alternative approaches.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.